Syndax Pharmaceuticals heads into its third-quarter report with a credibility test that has little to do with the headline numbers. Last quarter, new patient starts for Revuforge, its menin inhibitor for acute leukemia, fell to about 250 from roughly 330, the first sequential decline after six straight quarters of gains. Management called it an anomaly and declined to say anything about July. The stock has since lost 22.6%, trailing the S&P 500 by more than 20 percentage points. That gap suggests the market treated the drop as a possible turning point rather than a rounding error. The November 2 release, due after the close, is the first real chance to settle that argument.

The Street is looking for revenue of $81.1 million, up 76.8% from $45.9 million a year ago and roughly 11% above last quarter's $72.8 million. Consensus calls for a loss of $0.51 per share, narrower than the $0.55 loss in the second quarter and the $0.70 loss a year earlier. Syndax does not provide revenue guidance, so the sales line has no management range to anchor it. The one firm commitment is cost discipline. The company reaffirmed combined R&D and SG&A spending of about $400 million for 2026, excluding roughly $50 million of stock compensation. If expenses stay on that track, the steady shrinking of losses depends mostly on whether the top line keeps compounding.

An 11% sequential gain is roughly what Revuforge delivered last quarter, when sales rose 12% to $55 million. The bullish case is that duration can carry growth even if new starts are lumpy. The post-transplant maintenance restart rate climbed to about 50% from roughly 45%, against a steady-state target of 70% to 80%. Post-transplant patients now stay on therapy for more than nine months on average, and non-transplant patients for more than seven. Longer treatment builds a recurring revenue base, which cushions a soft intake quarter. Further progress on restart rates and duration would support management's newly explicit framing of more than $2 billion in US peak sales including frontline use. A rebound in new starts toward the prior run rate would go further and largely dispel the anomaly explanation. Another quarter near 250, especially with more talk of competitive pressure in the NPM1 subtype or trial enrollment pulling patients away, would make the decline look structural.

Nictimbo, the company's chronic graft-versus-host disease therapy, is the second swing factor. Sales grew 9% sequentially to $60 million, a slower pace that prompted analysts to ask about flattening. Market share in third-line-plus treatment edged up to about 33%, and nearly 90% of top-tier accounts are ordering, so broad adoption is not the issue. The question is whether deeper usage can restore growth now that most target accounts are already on board. Another single-digit sequential gain would reinforce the maturing narrative.

Sentiment remains bearish but has softened, improving to -0.26 from -0.335 before the last report. At $13.40, the stock sits well below its 200-day moving average of $20.42 and only about 5% above its post-earnings low of $12.80. The trading range has shifted sharply lower from the prior quarter's $16.66 to $25.24 band. That points to a stock priced for disappointment. A $575 million cash position, bolstered by a low-cost $250 million convertible, removes near-term financing worries. Upcoming fourth-quarter readouts for axotilamab in idiopathic pulmonary fibrosis and frontline chronic GVHD give investors reasons to look past this print.

In the end, this report comes down to Revuforge new patient starts. If intake recovers while duration keeps lengthening, the second-quarter dip becomes the anomaly management described, and the steep selloff looks overdone. If starts stay stuck, even a revenue beat may not repair confidence in the launch's trajectory.